The single use, however, of an H1R inhibitor Levocetirizine or an H2R inhibitor Cimetidine when H3R is functional appears to be promising since both drugs were effective in preventing the development of clinical signs and mortality due to CM. The gene discussed is HRH1; the disease is cutaneous mastocytosis.